SAB Biotherapeutics (SABS) Change in Account Payables (2021 - 2026)
SAB Biotherapeutics (SABS) reported Change in Account Payables of $114119.0 for Q1 2026, down 83.32% on a YoY basis from $684171.0 in Q1 2025, and down 64.84% quarter-over-quarter from $324527.0 in Q4 2025.
SAB Biotherapeutics (SABS) Change in Account Payables (2021 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Change in Account Payables for 6 years, with the latest figure at $114119.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 83.32% year-over-year to $114119.0; the trailing twelve-month figure through Mar 2026 stood at $912741.0 (down 33.09% YoY), and the FY2025 full-year result was $1.5 million, up 60.59% from the prior year.
- Change in Account Payables for Q1 2026 stood at $114119.0, down from $324527.0 in the prior quarter.
- The five-year high for Change in Account Payables was $684171.0 in Q1 2025, with the low at -$2.2 million in Q1 2023.
- Historically, Change in Account Payables has averaged -$56524.1 across 5 years, with a median of $134618.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Account Payables tumbled 94287.71% — and 2024, when it jumped 658.16%.
- SAB Biotherapeutics' Change in Account Payables stood at -$1.8 million in 2022, then jumped by 94.14% to -$105773.0 in 2023, then jumped by 658.16% to $590385.0 in 2024, then plunged by 45.03% to $324527.0 in 2025, then tumbled by 64.84% to $114119.0 in 2026.
- The last three Change in Account Payables figures came in at $114119.0 (Q1 2026), $324527.0 (Q4 2025), and $335924.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | 114,119.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 114,119.00 |
| Mar 31, 2026 | 114,119.00 |
| Dec 31, 2025 | 324,527.00 |
| Dec 31, 2025 | 324,527.00 |
| Sep 30, 2025 | 335,924.00 |
| Sep 30, 2025 | 335,924.00 |
| Jun 30, 2025 | 138,171.00 |
| Jun 30, 2025 | 138,171.00 |
| Mar 31, 2025 | 684,171.00 |
| Mar 31, 2025 | 684,171.00 |
| Dec 31, 2024 | 590,385.00 |
| Dec 31, 2024 | 590,385.00 |
| Sep 30, 2024 | 134,618.00 |
| Sep 30, 2024 | 134,618.00 |
| Jun 30, 2024 | -45,037.00 |
| Jun 30, 2024 | -45,037.00 |
| Mar 31, 2024 | 243,357.00 |
| Mar 31, 2024 | 243,357.00 |
| Dec 31, 2023 | -105,773.00 |
| Dec 31, 2023 | -105,773.00 |